Skip to main content

Closed

KAPA: Kairos Pharma, Ltd. Stock Analysis | finqOS

Healthcare · Biotechnology

Loading chart data...

Current StateBalance holding

The verdict

Good business

Weak

Revenue growth+0.0% / yr

Operating margin0.0%

ROIC-114.3%

Financially safe

Stretched

Debt / equity0.00×

Interest coverage0.0×

Current ratio10.31×

Kairos Pharma, Ltd.

KAPANew York Stock Exchange Arca·USD·Closed

Kairos Pharma, Ltd.

KAPANew York Stock Exchange Arca·USD·Closed

$0.33

+4.90%

$0.33

+$0.02 (4.90%)

52W Range

3thpctl

Volume

0.23×avg

Mkt Cap

6.96MUSD

P/E

-1.0TTM

Div Yield

–ann

52W Range

3thpctl

Volume

0.23×avg

Market Cap

6.96MUSD

P/E Ratio

-1.0TTM

Div Yield

-ann

Overview Financials Peers Sentiment Analysis Transcripts Holders Company SEC Filings

Overview Financials Peers Sentiment Analysis Transcripts Holders Company SEC Filings